Qualification of imaging biomarkers for oncology drug development

European Journal of Cancer

Volumn 48, Issue 4, 2012, Pages 409-415

  Waterton, John C ^a   Pylkkanen, Liisa ^b  

^a ASTRAZENECA   (United Kingdom)

^b EORTC DATA CENTER   (Belgium)

Author keywords

Biomarker qualification; Drug development; Imaging biomarkers; Public private partnerships

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESEARCH; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; ECHOCARDIOGRAPHY; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGANIZATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZATION; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; DIAGNOSTIC IMAGING; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857039823     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.11.037     Document Type: Article

References (20)

1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharm Ther 69 2001 89 95
2. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
3. S.N. Khleif, J.H. Doroshow, and W.N. Hait AACR-FDA-NCI Cancer Biomarkers Consensus Report: advancing the use of biomarkers in cancer drug development Clin Cancer Res 16 2010 3299 3318
4. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
5. J.P. O'Connor, A. Jackson, G.J. Parker, and G.C. Jayson DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents Br J Cancer 96 2007 189 195 (Pubitemid 46160619)
6. M.O. Leach, K.M. Brindle, and J.L. Evelhoch The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Br J Cancer 92 2005 1599 1610 (Pubitemid 40756468)
7. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology J Nucl Med 47 2006 901 903 (Pubitemid 46939939)
8. J.A. Wagner, S.A. Williams, and C.J. Webster Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs Clin Pharm Ther 81 2007 104 107 (Pubitemid 46050874)
9. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Qualification of novel methodologies for drug development: guidance to applicants. London, UK: European Medicines Agency; 2009 22 January 2009. Report No. EMEA/CHMP/SAWP/72894/2008 Corr1.
10. U.S. Department of Health and Human Services: Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry qualification process for drug development tools. Draft Guidance. October 2010.
11. M. Goldman Reflections on the innovative medicines initiative Nat Rev Drug Discov 10 2011 321 322
12. J.R. Bading, and A.F. Shields Imaging of cell proliferation: status and prospects J Nucl Med 49 Suppl. 2 2008 64S 80S (Pubitemid 351948037)
13. 18F]fluorothymidine Semin Nucl Med 37 2007 429 439 (Pubitemid 47498262)
14. J.S. Rasey, J.R. Grierson, L.W. Wiens, P.D. Kolb, and J.L. Schwartz Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells J Nucl Med 43 2002 1210 1217 (Pubitemid 34988769)
15. 18F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment Eur J Cancer 48 2012 416 424
16. D.A. Hamstra, A. Rehemtulla, and B.D. Ross Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology J Clin Oncol 25 2007 4104 4109 (Pubitemid 47495868)
17. D.M. Patterson, A.R. Padhani, and D.J. Collins Technology insight: water diffusion MRI - a potential new biomarker of response to cancer therapy Nat Clin Pract Oncol 5 2008 220 233 (Pubitemid 351493681)
18. R. Sinkus, B. van Beers, V. Vilgrain, N. DeSouza, and J.C. Waterton Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development Eur J Cancer 48 2012 425 431
19. 18F]ICMT-11 Eur J Cancer 48 2012 432 440
20. P. Lambin, E. Rios-Velazquez, and R. Leijenaar Radiomics: Extracting more information from medical images using advance feature analysis Eur J Cancer 48 2012 441 446